tailieunhanh - Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer

Inhibitors targeting immune checkpoints, such as PD-1/PD-L1 and CTLA-4, have prolonged survival in small groups of non-small cell lung cancer (NSCLC) patients, but biomarkers predictive of the response to the immune checkpoint inhibitors (ICIs) remain rare. | Zheng et al. BMC Cancer 2021 21 1322 https s12885-021-09044-4 RESEARCH Open Access Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer Yang Zheng1 Lili Tang2 and Ziling Liu1 Abstract Background Inhibitors targeting immune checkpoints such as PD-1 PD-L1 and CTLA-4 have prolonged survival in small groups of non-small cell lung cancer NSCLC patients but biomarkers predictive of the response to the immune checkpoint inhibitors ICIs remain rare. Methods The nonnegative matrix factorization NMF was performed for TCGA-NSCLC tumor samples based on the LM22 immune signature to construct subgroups. Characterization of NMF subgroups involved the single sample gene set variation analysis ssGSVA and mutation copy number alteration and methylation analyses. Construction of RNA interaction network was based on the identification of differentially expressed RNAs DERs . The prognostic predictor was constructed by a LASSO-Cox regression model. Four GEO datasets were used for the validation analysis. Results Four immune based NMF subgroups among NSCLC patients were identified. Genetic and epigenetic analy- ses between subgroups revealed an important role of somatic copy number alterations in determining the immune checkpoint expression on specific immune cells. Seven hub genes were recognized in the regulatory network closely related to the immune phenotype and a three-gene prognosis predictor was constructed. Conclusions Our study established an immune-based prognosis predictor which might have the potential to select subgroups benefiting from the ICI treatment for NSCLC patients using publicly available databases. Keywords NSCLC Immune subtype Immune checkpoint inhibition Multi-omics analysis Introduction landscape between LUAD and LUSC and in each sub- Lung cancer remains the largest cause of cancer deaths type itself 4 7 . Consequently lung cancer treatment is globally 1 . With non-small cell lung cancer NSCLC no longer .

• Y khoa - Dược
• BMC Cancer
• Immune subtype
• Immune checkpoint inhibition
• Multi omics analysis
• Prolonged survival
• Biomarkers predictive
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study